Lakefront Biotherapeutics (LKFT) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Lakefront Biotherapeutics (NASDAQ: LKFT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $32.28 (-0.15% 1D, market cap $2.13B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LKFT ranks #216 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LKFT carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SEPN (Septerna Inc.) holds a C grade (63/100 RQD, P/E N/A, ROIC -20.7%, cap $2.11B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.16B). Among the 5-stock peer group, LKFT leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
For Lakefront Biotherapeutics (LKFT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #216 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 1.5% FCF Margin ($59.7M FCF) & 52% Gross Margin
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 56/100 (D+) score, LKFT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.56) or 200D SMA ($29.91) invalidates the momentum regime and cuts Target Base ($31.99) toward Bear Floor ($24.95).
Lakefront Biotherapeutics (LKFT) slipped -0.15% to $32.28, trading at 63% of its 52-week range ($25.68 – $36.24). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
Investing.com India report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
TipRanks report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext &
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LKFT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LKFT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Lakefront Biotherapeutics (LKFT) ranks #216 by composite RQD confidence (56/100, grade D+) and #252 by equity capitalization ($2.13B). Within this direct 5-issuer industry benchmark cohort, LKFT leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with LKFT at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LKFT
ACTIVE
Lakefront Biotherapeutics | D+ | 56/100 | — | — | — | -0.15% | $2.13B | Benchmark Subject |
| SEPN Septerna Inc. | C | 63/100 | — | — | -20.7% | -2.72% | $2.11B | /sepn-vs-lkft → |
| IMNM Immunome Inc. | E | 26/100 | — | — | -35.0% | -0.44% | $2.16B | /imnm-vs-lkft → |
| XNCR Xencor Inc. | D | 47/100 | — | — | -21.3% | +2.09% | $2.17B | /xncr-vs-lkft → |
| PVLA Palvella Therapeutics Inc. | D | 47/100 | — | — | -27.9% | -3.58% | $2.18B | /pvla-vs-lkft → |
Lakefront Biotherapeutics (LKFT) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.13B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Lakefront Biotherapeutics (NASDAQ: LKFT) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $32.28 (-0.15% 1D, market cap $2.13B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LKFT ranks #216 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LKFT carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SEPN (Septerna Inc.) holds a C grade (63/100 RQD, P/E N/A, ROIC -20.7%, cap $2.11B) and IMNM (Immunome Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $2.16B). Among the 5-stock peer group, LKFT leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).
For Lakefront Biotherapeutics (LKFT), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #216 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
LKFT last traded at $32.28 (-0.15% on volume of 164,059 shares), positioning the stock +9.20% above its 50-day simple moving average ($29.56) and +7.92% above its 200-day simple moving average ($29.91). Across its 52-week range of $25.68 to $36.24, LKFT sits at the 62.5% percentile with a 14-day RSI of 70.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±5.1% ($30.63 to $33.93).
Why LKFT Stock slipped -0.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, LKFT scores 56 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars break down as follows. Fundamental Cash Engine scores 12 of 20, with ROIC at 0% and FCF yield at 0%, indicating the source data shows no measurable return on invested capital or free-cash-flow generation. Whale 13F Flow scores 12 of 20, reflecting institutional accumulation and options positioning. Insider Conviction scores 9 of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit scores 10 of 20, with a Beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 13 of 20, reflecting an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.
For a prospective investor evaluating the stock today, the rating points to a mixed picture. The weakest pillar is insider conviction, and the cash-generation pillar is weak because the source data reports zero ROIC and zero FCF yield, which leaves valuation tradeoffs difficult to assess on earnings or cash-flow terms. The balance sheet pillar is the relative strength, with a Piotroski F of 6/9 and a Debt/Equity of 0.5. Beta of 1.0 implies the stock moves in line with the broader market per the source data, so macro sensitivity is not an outlier. Potential upside drivers in the source data are limited to the positive news items described below; the rating itself frames the overall posture as trim rather than accumulate.
Per the recent news and catalysts section, the following items are listed:
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no upstream or downstream dependencies, no sector correlations, and no proprietary signals provided. Not available in source data for upstream/downstream dependencies, sector correlations, or 2nd-order bottlenecks.
Real-time company headlines, analyst actions, and sector developments for Lakefront Biotherapeutics (LKFT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
Investing.com India report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
TipRanks report covering Lakefront Biotherapeutics (LKFT) market action, institutional positioning, and fundamental catalysts.
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board Mechelen, Belgium; November 2, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext &
Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.
Welcome to the LKFT (Lakefront Biotherapeutics) Roar Pit. Current RQD Composite is 56/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on LKFT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lakefront Biotherapeutics expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on LKFT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $32.33 (52-wk range $25.68 - $36.24), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).